Home » Posts tagged 'raghundan vikram'
Tag Archives: raghundan vikram
Correlation of CT Derived Texture Features with Mutational Status of Clear Cell Renal Carcinoma using TexRAD
Correlation of CT Derived Texture Features with Mutational Status of Clear Cell Renal Carcinoma using TexRAD – Preliminary Findings
Sahand Sohrabi and Raghunandan Vikram – Diagnostic Imaging, MD Anderson Cancer Center, Houston, Texas, USA
Purpose: To investigate role of CT Texture analysis (CTTA) and mutational status of clear cell renal cell carcinoma (ccRCC).
Materials and Methods: Multi-phase contrast enhanced CT (CECT) including Non contrast (NC), Corticomedullary (CM), nephrographic (N) and excretory (E) of 107 patients with ccRCC from the Cancer Imaging achive underwent filtration-histigram based CTTA using a commercially available research software (TexRAD Ltd). Using the DICOM images, filtration step extracted texture features using different spatial scale filters corresponding to fine, medium and coarse texture scales followed by histogram quantification: Mean gray-level pixel intensity, Entropy, Standard Deviation (SD), Mean of positive pixels (MPP), Kurtosis and Skewness. Non-parametric Mann Whitney test was used to test for significant associations in CTTA with mutational status (VHL, BAP1, PBRM1, SETD2, P13K pathway regulators.
Results: NC study showed statistically significant differences in the CT derived textual features between the mutational status of BAP1 (entropy p=0.045; SD p=0.033; MPP p=0.03), VHL (mean p=0.049, SD0.031), P13 pathway regulator (mean p=0.021, SD p=0.03, MPP p=0.03, skewness p=0.048) and PBRM1 (skewness p=0.048). Differences in CTAA measurements were seen in all phases in patients with VHL mutational status. These were most marked in the CM phase (mean p=0.031, SD p=0.006, entropy p=0.03, MPP p=0.005 and Kurtosis p=0.049). CTA measurements in Excretory phase images were useful in differentiating between BAP one mutations (entropy p=0.045, skewness p=0.035) and PBRM1 mutations (entropy p=0.023).
Conclusions: A software-based CT Texture Analysis can derive features that may help identify patients with genetic mutations in patients with ccRCC.
Dr Balaji Ganeshan, Director of New Business at Feedback Plc stated, “In our trading update of March 30th 2017, we stated that purchase orders for the well-established research version of TexRAD continued at a good rate ahead of the impending release of the first clinical version. This study is the latest in a number of published papers that serves to demonstrate the value and diversity of TexRAD for CTTA applications, and further underscores the progress highlighted in the trading update. We remain focussed on obtaining the CE mark for TexRAD Lung by the target date of May 2017.”